ibrutinibB-cell malignanciesEur J Drug Metab PharmacokinetCancer Chemother Pharmacol
…cal scenarios (n=144) combining the main covariates influencing ibrutinib exposure. Under standard conditions (420 mg/day, fasting), pred…
7articles mentioning drugs
17drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Ibrutinib ×
Ibrutinib
This drug is selected. Its supporting articles are shown below.
Articles mentioning Ibrutinib
7 articles · page 1 of 1ibrutinibvenetoclaxvenetoclax-inducedI+VCLLchronic lymphocytic leukaemia
…ed apoptosis.The I+V regimen consists of three 28-day cycles of ibrutinib monotherapy, followed by the addition of venetoclax from cycle …
ibrutinibIBRCLLchronic lymphocytic leukaemiapharmaceutical care programprimary care hospital
…Background and Importance Although ibrutinib (IBR) is effective across all treatment lines for chronic lymph…
ibrutinibbreast cancernon-Hodgkin lymphomachronic lymphocytic leukaemia
…resent the case of radiation recall dermatitis (RRD) induced by ibrutinib therapy in a patient with a history of breast cancer and non-Ho…
bosentandaratumumabazacitidineibrutinibnintedanibrare diseasesRDORPHANETnational health authorities
… (14.8%), nintedanib (11.3%), ibrutinib (10%), azacitidine, and bosentan (7.8%). OD distribution by ATC group was dominated by L (n=19),…
venetoclaxibrutinibzanubrutinibacalabrutinibBTKiBCL2ichronic lymphocytic leukaemiaCLL
…brutinib (40.7%), acalabrutinib (30.5%), zanubrutinib (3.4%) or venetoclax (25.4%). 91.5% of them had at least one comorbidity and the med…
ibrutinibrituximabhigh-dose intravenous methylprednisoloneDipeptidyl-peptidase-like protein-6 (DPPX) antibody-associated encephalitisImmunotherapychronic lymphocytic leukaemia (CLL)CLLB-cell neoplasmsanti-DPPX encephalitis
…months later his ACE-III score improved to 72/100. He commenced ibrutinib to prevent relapses of anti-DPPX encephalitis and CLL in future…